A pioneering drug has been developed which slows brain decline in Alzheimer’s patients.
Experts said “this could be the beginning of the end” of the disease after donanemab slowed decline by 36% in a late-stage clinical trial.
Drugmaker Eli Lilly and Company said the drug appeared to slow progression compared to a placebo in 1,182 people with early-stage disease by targeting a protein in the brain known as tau.
